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The low minimal inhibitory concentrations and minimal bactericidal concentrations of
the quinolones for most pathogenic gram-negative and many gram-positive organisms,
the ease of their administration, and their good oral absorption make them good candi-
dates for the treatment of chronic bone infections. Data presently available suggest that
the quinolones are effective in the treatment of experimental osteomyelitis due to Pseudo-
monas aeruginosa, osteomyelitis due to other gram-negative organisms, and (when com-
bined with rifampin) in the treatment of gram-positive osteomyelitides. Quinolones have
also been shown to be effective in the treatment of experimental septic arthritis. These
results were confirmed by clinical studies. Quinolones have been effective in the treat-
ment of patients with gram-negative bacterial bone infections and have been as effective
as conventional antistaphylococcal therapy in the treatment of osteomyelitis due to Staph-
ylococcus aureus. Finally, it should be kept in mind that as yet quinolones have not been
released for use as therapy for childhood infections.
Osteomyelitis and, to a lesser extent, some cases of
septic arthritis represent a wide field of potential use
for the new quinolones, since these diseases are
characterized by a high frequency of failures of ther-
apy and recurrence of infection due to short-term
treatment, inadequate choice of antibiotic, forma-
tion of abscess and sequestrum, and other as yet un-
known factors [1]. These failures of therapy are also
partly influenced by the use of orthopedic fixation
devicesand prosthetic implants of various types that
perpetuate the infectious process. Consequently, the
development of a new group of antimicrobial agents
that havebetter activity against microorganisms com-
monly isolated in patients with acute and chronic
osteomyelitis and arthritis, that can be administered
over prolonged periods either by the parenteral or
oral routes, that have a low frequency of adverse ef-
fects, and that have high clinical efficacy has been
the ultimate goal and secret hope of many orthope-
dic surgeons, microbiologists, and specialists in in-
fectious disease. Whether the quinolones represent
such a panacea is discussed in this presentation.
Microbiologic Aspects
The spectrum of microorganisms responsible for os-
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teomyelitis and septic arthritis is summarized in ta-
ble 1 [2-4]. In short, whether dealing with osteomye-
litis of hematogenous type or of the contiguous type,
Staphylococcus aureus and Staphylococcus epider-
midis together are still the organisms encountered
most frequently. Hematogenous osteomyelitis of the
long bones can also be caused by group B strep-
tococci (in neonates), Haemophilus influenzae (in
infants), and, in the spine, by gram-negative organ-
isms. Hematogenous disease, however, occurs most
often at an age when the use of quinolones has, at
this writing, been contraindicated, because of previ-
ous experience with nalidixic acid and new experi-
mental data showing malformations due to exposure
to quinolones during the development of limb buds.
In addition, adults are afflicted in two different
waysby osteomyelitis. Vertebral osteomyelitis is due
to both staphylococci and gram-negative rods [5].
Osteomyelitis contiguous to a focus of infection
(such as those that occur after trauma or surgery)
can be due to staphylococci and a variety of gram-
negative rods, often in mixed cultures. One ideal
property of any new agent (namely, low MIC or low
MBC for these microorganisms) is certainly charac-
teristic of the quinolones with respect to gram-
negative organisms, including Pseudomonas aeru-
ginosa, but to a lesser extent with respect to S. aureus
and S. epidermidis-the MICs of quinolones are
similar to, or sometimes higher than, those reported
for the commonly used antibacterial agents. An ex-
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S. aureus ++ ++
S. epidermidis + ++
Group B streptococci
(neonate) + (+)
H. influenzae (infant) (+) 0
Adults
S. aureus + ++
S. epidermidis + ++
Gram-negative
organisms ++ +
NOTE. Frequency ranges from low (0) to high (+ + ).
* Refers to osteomyelitis of the spine in adults.
ception to this rule may be the methicillin-resistant
S. aureus; the MIC of quinolones for these organ-
isms is only slightly higher than the MICs of their
sensitive congeners. The search for new quinolones
with lower MICs for staphylococci and other gram-
positive organisms should be pursued in the future.
Another aspect to be discussed is whether the
quinolones are active under the stringent phys-
icochemical conditions of a focus of osteomyelitis
or arthritis, characterized by a low pH [6] and low
Po, [7]. Kill curves for difloxacin and A56620, de-
termined under aerobic (100mm Hg) and anaerobic
(10mm Hg) conditions have shown both antibiotics
to be equally effective under both conditions [8].
Lowering of the pH dramatically increased the MIC
of some, but not all, quinolones [9], a finding that
suggests the influence of pH should be explored for
each individual quinolone.
With respect to septic arthritis, the quinolones are
certainly effectiveagainst Neisseria gonorrhoeae and
the gram-negative rods isolated from septic joints,
but the comments regarding osteomyelitis are ap-
plicable here-the available data concerning MICs
for S. epidermidis,S. aureus, and streptococci show
no great advantage of the quinolones when com-
pared with the standard antibiotics presently used
for the treatment of patients with bone and joint in-
fections [10, 11].
Difficulties in Evaluating the
Efficacy of the Quinolones
Problems in the evaluation of the efficacy of the
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quinolones arise because bone is a heterogeneous
structure [12]. Differences in bone matrix and crys-
tal density between cortex and medulla; differences
in blood supply between cortex, medulla, and peri-
osteum; and differences in fluid space between in-
fected and noninfected bone willaffect the measure-
ment of levels of antibiotic in bone. This difficulty
in measurement can be rectified in part by the in-
troduction of correction factors such as assays of he-
moglobin [13] or myoglobin [14] Extraction proce-
dures, although wellstandardized, have shown either
incomplete [14] or prolonged back diffusion of
quinolones [15]. Finally, there are good reasons to
believe that distribution of antibiotic is not uniform
in a heterogeneous structure such as bone, and it can
be hypothesized that the effects of nalidixic acid on
developingbone or of quinolones on developing limb
buds may be due to specific local accumulation of
these compounds. In summary, small differences
found in levelsof quinolones in bone should not be
attributed to the substances themselves, but rather
to methodologic factors. In addition, interpretation
of the data implies a careful evaluation of the ex-
traction procedure, the control of blood contami-
nation, and the standardization curves.
Other factors render the evaluation of the quino-
lones in clinical settings difficult [16]. For instance,
none of the 25 studies reported by 1987concerning
the use of ciprofloxacin in the treatment of osteomye-
litis have been controlled, despite the inclusion of
more than 100patients [16]. The reasons for the lack
of data from controlled trials are evident and un-
avoidable: acute vs. chronic disease, the type of or-
ganisms involved, the mode of infection, the pres-
ence of foreign material, previous or concomitant
surgery, and previous antibiotic therapy introduce
so many variables into each individual patient that
no clinical study will ever solve the statistical prob-
lem of the 13 error. This problem can be avoided in
part by testing quinolones in experimental infections.
Experimental Osteomyelitis and Arthritis
In a recent study, Norden and Skinner [17] have
shown a 95070 cure rate of osteomyelitis due to P.ae-
ruginosaafter 4 weeks of treatment with ciproflox-
acin vs. a 6% cure rate with tobramycin. Impressive
as these results are, the investigators also showed that
20% of the organisms isolated at 2 weekshad a four-
fold to 16-fold increase in the MIC of ciprofloxa-
cin. Under similar experimental conditions, these in-
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vestigators analyzed the efficacy of ofloxacin. Levels
of drug in serum and bone of 5 mg/L at 2 hours
and 1.7mg/L at 6 hours, respectively, were achieved.
They found that 94010 of the rabbits had positive cul-
tures before administration of drug and only 6% had
positive cultures after 28 days of treatment. No in-
crease in the MIC for the isolated strain of P. aeru-
ginosawas observed in this study. These results were
better than those recorded previouslywith carbenicil-
lin, azlocillin, and sisomycin [18].
Experimental results are less convincing with re-
spect to S. aureus. In two studies from the Mayo
Clinic that were performed in rats, 3 weeks oftreat-
ment with ciprofloxacin led to the same results as
those obtained with nafcillin on a methicillin-sensi-
tive organism [19, 20]. A 3-weektreatment with van-
comycin or ciprofloxacin of osteomyelitis due to
methicillin-resistant organisms gave equally poor
results. Combination therapy with vancomycin plus
rifampin was less effective than a combination of
ciprofloxacin plus rifampin, the only effective mode
of treatment. In a careful study on experimentally
induced chronic osteomyelitisdue to S. aureusin rab-
bits, Mader et al. [8] compared the effects of nafcil-
lin (40 mg/kg four times daily) and two aryifluoro-
quinolones, A56619 (difloxacin) and A56620 (15
mg/kg or 20 mg/kg administered subcutaneously
twicedaily). All three treatments werestarted 2 weeks
after induction of infection and continued for 4
weeks; the animals were killed 2 weeks after com-
pletion of therapy. The MIC for the strain of S. au-
reusused to cause the infection was the same for the
quinolones and for nafcillin (0.39 mg/L). Thus,
equivalent experimental conditions were created to
compare a well-established antibiotic with the new
quinolones. Identically good results were obtained
with nafcillin (sterilizations, 12 of 20) and difloxa-
cin (sterilizations, 14 of 20).
Taken together, these results suggest that the
quinolone used was as effective as a 13-lactamase-
stable penicillin for the treatment of osteomyelitis
due to methicillin-sensitive organisms. With respect
to methicillin-resistant organisms, a combination of
a quinolone and rifampin seemed to give the most
favorable, albeit suboptimal, results. In the treatment
of gram-negative osteomyelitis(for the most part due
to P. aeruginosa) quinolones definitely fared better
than other combinations.
In a recent study of experimental gram-negative
arthritis in rabbits, the effect of ciprofloxacin was
compared with the activity of gentamicin [21]. The
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offending organism was a pathogenic, serum-resis-
tant strain of Escherichia coli isolated from a pa-
tient with neonatal meningitis. The joints of rabbits
were injected with 108 organisms. Four days later the
rabbits were randomly assigned to receive either in-
tramuscular ciprofloxacin (80 mg/kg daily) or in-
tramuscular gentamicin (5 mg/kg daily) for 17days.
Maximal levels of ciprofloxacin in serum and joint
were always higher than the MBC for the strain of
E. coli, whereas this was exceptionally the case for
gentamicin. As expected, ciprofloxacin fared much
better than gentamicin: ciprofloxacin was bacteri-
cidal in all cases at day 10 and in all but one case
at day 17. In contrast, gentamicin was bactericidal
in only six of 18joint fluids at day 10 and in eight
of 10 at day 17. Similar differences were obtained
when synovial tissue was assessed. The comparison
of ciprofloxacin vs. gentamicin showed the same
beneficial effect of quinolones when the results were
expressed in terms of residual colony-forming units.
Clinical Studies
A variety of studies have addressed the question of
the efficacy of quinolones for treatment of patients
with chronic osteomyelitis due to gram-negative aer-
obic organisms. In a study of 34 patients with gram-
negative osteomyelitis who were treated with oral
ciprofloxacin (750 mg twice daily for 6-24 weeks),
Lesse et al. [22] reported on 23 evaluatable patients,
nine of whom were still receiving treatment. These
investigators found that 11 of 23 patients had poly-
microbial infection - a disputed entity - fiveof these
infections involved S. aureus, for which the patients
received additional antistaphylococcal treatment.
The authors reported an astonishing success rate of
23 of 23 patients, but, as mentioned above, only 14
patients had completed therapy and the follow-up
period was short (mean, 6 months), while nine pa-
tients werestill receivingtreatment. A study of gram-
negative chronic osteomyelitis in 20 patients was per-
formed by Gilbert [23] with the same dosage of
ciprofloxacin and a period of treatment of 6-10
weeks. Three patients had osteomyelitis of the ster-
num, and 17patients had osteomyelitis of the lower
extremities. P.aeruginosa was isolated from the site
of infection in 13 patients; 15patients underwent ad-
ditional debridement. Results at 7-21 months follow-
up showed a 65% clinical cure rate and a 70OJo micro-
biologic cure rate, with slightly less satisfactory
results in cases of infection due to P.aeruginosa. The
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MIC for strains of P. aeruginosa increased during
therapy.
Two other series of patients with chronic gram-
negative osteomyelitides who were given a similar
regimen of ciprofloxacin (750 mg twice daily) have
been published. In the study by Trexler [24], 22 of
24 patients were evaluatable, 16 patients also had sur-
gical procedures performed, and eight patients were
given additional antibiotic treatment. At follow-up
after more than 6 months, 20 of 22 patients were
determined to be cured on the basis of clinical,
microbiologic, and radiologic findings. In the study
by Slama [25],there were 10acute and 20 chronic cases
of osteomyelitis, including eight patients with ster-
nal infections. Clinical and bacteriologic control was
achieved in 22 of 30 patients; the eight recurrences
of infection responded to a second course of cipro-
floxacin therapy and debridement. Finally, Green-
berg [26] performed as good a randomized study as
possible in this disease with so many variables: he
randomly assigned 30 patients to receive either ci-
profloxacin (750 mg twice daily) or "appropriate che-
motherapy" (most often a combination of two paren-
teral antibiotics, one of which was usually an
aminoglycoside). The results were slightly better with
combination therapy than with the quinolone. In 16
patients there were 11 "cures," four improvements,
and one failure with combination therapy. In 14 pa-
tients there were seven "cures," three improvements,
and four failures with quinolone therapy. The same
trend was observed for infections due to P. aerugi-
nosa. Noteworthy is the high rate of complications
with combination therapy (five of 16patients), which
must be weighed against the good tolerance of
ciprofloxacin. Overall, the occurrence of adverse ef-
fects with the quinolone [22-26] was rare and incon-
sequential. These results suggest that in patients with
gram-negative osteomyelitis, treatment with
quinolones - particularly ciprofloxacin - achieves
cure rates >50070 in most cases and represents an in-
teresting alternative to conventional parenteral che-
motherapy with its inherent complications.
The interpretation of the results achieved in os-
teomyelitis due to gram-positive organisms or of
mixed etiology is more difficult. In an open study,
Ramirez [27] treated and cured three cases of arthri-
tis due to N. gonorrhoeae and S. pneumoniae with
ciprofloxacin. Remarkable results were obtained by
Desplaces et al. [28] with a combination of pefloxa-
cin (400 mg twice daily) plus rifampin in patients
with chronic osteomyelitis due to S. aureus. Four-
teen of 14 patients were cured, with a follow-up of
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9-24 months, results that confirm the experimental
data described previously. Similar results were re-
ported by Dellamonica [15] with the use of pefloxa-
cin in 15patients with chronic osteomyelitis, five of
whom had infection due to S. aureus.
A long list of abstracts describing small numbers
of cases of osteomyelitis treated with quinolones
could be added to this enumeration. In addition,
many investigators, deeply impressed by the favor-
able results obtained with quinolones, have expressed
their enthusiasm by presenting the same data at sev-
eral congresses, thereby artificially improving the
overall cure rate. These studies do not help in the
assessment of the efficacy of the quinolones for
the treatment of chronic osteomyelitis. Care should
also be given to an objective assessment, with ade-
quate follow-up, of failures of treatment.
Conclusions and Remaining Problems
Quinolones have many characteristics (including
their low MIC and MBC for most bone pathogens)
that make them suitable as effective agents for the
treatment of bone and joint infections due to gram-
negative and gram-positive organisms. However, im-
proved efficacy against S. aureus and S. epidermidis
is a desirable attribute of compounds yet to be de-
veloped. Levels of drug in bone in experimental sys-
tems and in human bone biopsies are adequate to
be effective against most bone pathogens, although
efficacy may be limited by possible heterogeneous
intraosseous distribution of the antibiotic. Experi-
mental models of osteomyelitis have shown the quin-
olones to be effective, particularly in infections due
to P. aeruginosa, but also in other bone and joint
infections due to gram-negative organisms. These
results suggest the use of combination therapy (with
rifampin, for instance) for the treatment of infec-
tions due to gram-positive organisms. Clinical studies
demonstrate that results of treatment with qui no-
lones of bone infections due to gram-negative organ-
isms are similar to or better than results of treatment
with conventional parenteral combination therapy.
Despite many anecdotal reports of the efficacy of
quinolones for the treatment of'staphylococcal in-
fections, the pooled data are still inconclusive. Com-
bination therapy with a quinolone plus another agent
should be suggested until more studies are available.
Large studies are still to be encouraged to further
clarify the role of the quinolones in the treatment
of bone and joint infections.
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